Neurology INDICATION: Anxiety In vitro and mouse studies identified a CRHR1 antagonist that could help treat anxiety. Chemical synthesis and in vitro testing of benzimidazole analogs identified a compound that bound CRHR1 with a Ki...

Sera Prognostics Inc. is developing a molecular test that it thinks will accurately predict more than 90% of women at risk for preterm birth, allowing earlier monitoring and preventive treatment. The company raised $19.3 million...

Approach Summary Licensing status Publication and contact information Drug delivery Lentiviral-based method of gene therapy to treat CNS disorders A method for delivering and activating genes in the CNS could help treat neurological diseases. A...

The companies will terminate on Dec. 8, their 2001 deal to develop therapeutics against corticotrophin-releasing factor ( CRF1 ) for stress disorders, including depression and anxiety. The original deal was between NRGN and Aventis S.A., which merged...

The ability of Britain's Arakis to raise £29 million ($52 million) in a series C round has spurred some sector watchers to wonder if this will encourage a spate of investing in European companies that...

NRGN and Sanofi - Aventis S.A. (Euronext:SAN; SNY) will terminate on Dec. 8 their 2001 deal to develop therapeutics against corticotrophin releasing factor ( CRF1 ) for stress disorders, including depression and anxiety. The original deal was between...

NRGN received a $1 million milestone from AVE under the companies' 2001 deal to develop therapeutics against corticotrophin releasing factor ( CRF1 ). The payment was triggered by a preclinical milestone. Neurogen Corp. (NRGN), Branford, Conn....

AVE licensed exclusive worldwide rights to NRGN's corticotrophin releasing factor ( CRF1 ) antagonist compounds, including its lead, NGD 98-2, for use in treating depression, anxiety and other stress-related disorders. NRGN will receive a $10 million upfront...

AVE licensed exclusive worldwide rights to NRGN's corticotrophin releasing factor ( CRF1 ) antagonist compounds, for use in treating depression, anxiety and other stress-related disorders, including lead compound NGD 98-2. NRGN will receive a $10 million upfront...

NTII announced that Phase I/II testing of CRF reduced symptoms in 6 of 7 patients who received the longest duration of treatment with the factor. Symptoms assessed in the two open-label pilot trials included seizures,...